All In Biotech

Drug Trial Radar · NCT07467707

An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults

A Phase 3b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of an Adjuvanted Chikungunya Virus Virus-like Particle (CHIKV VLP) Vaccine for the Prevention of Chikungunya Disease in Adolescents (12 to <18 Years) and Adults (≥18 Years)

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 6,144 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

6,144

Planned (sponsor's estimate)

Start

May 26, 2026

Primary completion

May 2030

Study completion May 2030

Sponsor

Lead sponsor
Bavarian NordicIndustry
Sponsor type
Industry
Collaborators
Walter Reed Army Institute of Research (WRAIR); Congressionally Directed Medical Research Programs; United States Department of Defense; Pharmaceutical Product Development, (PPD) LLC; Armed Forces Research Institute of Medical Services; Q-square Business Intelligence, Inc.
First posted
Mar 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Study EBSI-CV-317-007 is a field study to evaluate the efficacy, immunogenicity, and safety of CHIKV VLP vaccine. The study was designed using infectious disease models and advanced analytics to guide region and clinical site prioritization, define the timing of study activities, and optimize the study parameters to local epidemiological conditions for CHIKV disease to overcome the challenges of assessing efficacy for CHIKV VLP vaccine.

Conditions

  • Chikungunya Virus

Interventions

  • CHIKV VLP vaccineBiological

    CHIKV VLP vaccine is comprised of 40 µg CHIKV VLP adsorbed on aluminum hydroxide (corresponding to approximately 300 µg of aluminum and stabilized with formulation buffer). CHIKV VLP vaccine is supplied as a single dose of 0.8 mL in a single use pre-filled syringe administered via IM injection in the deltoid muscle.

  • PlaceboBiological

    Placebo is comprised of formulation buffer supplied as a single dose of 0.8 mL in a single use pre-filled syringe administered via IM injection in the deltoid muscle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of laboratory-confirmed acute CHIKV diseaseTime frame: From 14 days postvaccination through end of study follow-up, up to 1095 days postvaccination

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • WRAIR-AFRIMS Philippines, Cebu (WRAIR-APC)

    Cebu City, Cebu, Philippines · Recruiting

  • Kamphaeng Phet Provincial Hospital

    Kamphaeng Phet, Changwat Kamphaeng Phet, Thailand · Recruiting

  • Songklanagarind hospital, Prince of Songkla University (PSU)

    Hat Yai, Changwat Songkhla, Thailand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.